Tenax Therapeutics Inc (TENX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.94+8.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TENX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete analysis and report topline results from the Phase 3 LEVEL clinical trial of TNX-103 in third quarter of 2026.
Stated as a priority in 3 disclosures including 2026-Q1 and 2026-Q2. Enrollment completed with over 230 patients randomized by 2026-Q1. Management expected topline data in Q3 2026 and confirmed presentation at ESC Congress in August 2026. The priority is delivering as planned with data reported and presented on schedule.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We expect to have topline data from the LEVEL clinical trial in August 2026.”
“We continued to make significant progress... to deliver topline data in the third quarter of 2026.”
Continue activating sites and enrolling patients in the second global pivotal Phase 3 LEVEL-2 trial, targeting completion by end of 2027.
Stated in 2 of last 2 quarters (2026-Q1 and 2026-Q2). Management reports ongoing site activation and enrollment advancement for LEVEL-2 trial with expected completion by end of 2027. No enrollment numbers disclosed yet, so progress is qualitative but consistent with stated timeline.
“Our team continues to activate sites and advance enrollment in LEVEL-2, expecting to complete enrollment by end of 2027.”
“Our team continues to activate clinical sites around the world to advance enrollment in LEVEL-2, with completion anticipated by end of 2027.”
Maintain sufficient cash and cash equivalents to fund company operations through at least 2027 or early 2028.
Stated in 3 quarters from 2025-Q4 through 2026-Q2. Cash and cash equivalents rose from $97.6M at 2025-Q4 to $118.0M at 2026-Q2, supported by $13.4M warrant proceeds in Q2 2026. Management extended cash runway to Q2 2028, consistent with stated funding priority and showing delivering trajectory.
“Proceeds from warrant exercises enabled extension of cash runway through second quarter of 2028.”
“Cash and cash equivalents expected to fund operations through at least first quarter of 2028.”
“Company expects cash and cash equivalents to fund operations through 2027.”
Enhance management capabilities by appointing experienced executives in financial and commercial roles.
Stated in 2 quarters (2026-Q1 and 2026-Q2). Management appointed a new CFO and Chief Commercial Officer in early 2026, reinforcing leadership. This priority shows delivering progress with concrete executive hires.
“Leadership team strengthened with key executive appointments including CFO and CCO.”
“Appointed Thomas Staab as CFO and Timothy Healey as Chief Commercial Officer.”
Utilize the supply agreement with Orion Corporation as primary supplier for oral levosimendan product development and commercialization.
Newly stated in mid-2026 via material definitive agreement. The supply agreement with Orion was exercised to secure supply for development and commercialization. No financial or volume data disclosed yet, so progress is early and qualitative.
Over the trailing year it converted 0.62x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.